Treatment of canine old world visceral leishmaniasis: A systematic review

Veterinary Dermatology

Volumn 16, Issue 4, 2005, Pages 213-232

  Noli, Chiara ^a   Auxilia, Silvia T ^b  

^a Ospedale Veterinario Cuneese   (Italy)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; MEGLUMINE;

ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOG; DOG DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; LEISHMANIASIS, VISCERAL; MEGLUMINE; RANDOMIZED CONTROLLED TRIALS;

LEISHMANIA INFANTUM; PHLEBOTOMINAE;

EID: 24644524243     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2005.00460.x     Document Type: Review

References (60)

1. Slappendel RJ, Ferrer L. Leishmaniasis. In: Greene CE ed. Infectious Diseases of the Dog and Cat, 2nd edn. Philadelophia: W.B. Saunders, 1998: 450-8.
2. Ciaramella P, Corona M. Canine leishmaniasis: clinical and diagnostic aspects. Compendium 2003; 25: 358-68.
3. Pinelli E, Killick-Kendrick R, Wagenaar J et al. Cellular and humoral immune response in dogs experimentally and naturally infected with Leishmania infantum. Infective Immunology 1994; 62: 229-35.
4. Rhalem A, Sahibi H, Lasri S et al. Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment. Veterinary Immunology and Immunopathology 1999; 71: 69-79.
5. Baneth G, Shaw SE. Chemotherapy of canine leishmaniosis. Veterinary Parasitology 2002; 106: 315-24.
6. Ciaramella P, Corona M. Canine leishmaniasis: therapeutic aspects. Compendium on Continuing Education for the Practicing Veterinarian 2003; 5: 370-5.
7. Von Tscharner C, Halliwell REW, eds. Advances in Veterinary Dermatology, Vol. 1. London: Baillière Tindall, 1990.
8. Ihrke PJ, Mason IS, White SD, eds. Advances in Veterinary Dermatology, Vol. 2. Oxford: Pergamon Press, 1993.
9. Kwochka KW, Willemse T, Von Tscharner C, eds. Advances in Veterinary Dermatology, Vol. 3. Oxford: Butterworth Heinemann, 1998.
10. Thoday KL, Foil CS, Bond R, eds. Advances in Veterinary Dermatology, Vol. 4. Oxford: Blackwell Science, 2002.
11. Olivry T, Mueller RS. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Veterinary Dermatology 2003; 14: 121-46.
12. Mueller RS. Treatment protocols for demodicosis: an evidence-based review. Veterinary Dermatology 2004; 15: 75-89.
13. Reiter I, Kretzschmar A, Boch J et al. Zur Leishmniose des Hundes. Infektionsverlauf, Diagnose und Therapieversuche nach exp. Infektion von Beagles mit Leishmania donovani (St. Kalkutta). Berliner Muenchner Tieraerztlicher Wochenschrift 1985; 98: 40-4.
14. Reusch C, Reiter I. Die importierte Hundeleishmaniose: Ehrfahrungen zu Klinik, Diagnostik und Therapie mit Na-Stiboglucont (Pentostam). Tieraerztliche Praxis 1987; 15: 305-10.
15. Bergeaud P. L'apport de la corticothérapie dans le traitement de certaines formes de leishmaniose canine: Résultats sur une série de quarante-trois cas. Pratique Médicale et Chirurgicale de l'Animal de Compagnie 1988; 5: S121-6.
16. Mancianti F, Gramiccia M, Gradoni L et al. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 1988; 82: 566-7.
17. Slappendel RJ. Canine leishmaniasis. A review based on 95 cases in the Netherlands. Veterinary Quarterly 1988; 10: 1-16.
18. Berenger A. Proposition d'une odalité particulière de traitement de la leishmaniose canine: guérison possible. Pratique Médicale et Chirurgicale de l'Animal de Compagnie 1988; 5: S111-19.
19. Deplazes P, Arnold P, Skaggs J et al. Parasitologische und immunologische Verlaufskontrollen waehrend und nach Chemotherapie der Leishmaniose de Hundes. Schweizer Archiv Fuer Tierheilkunde 1992; 134: 85-93.
20. Neogy AB, Vouldoukis I, da Costa JM et al. Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Veterinary Parasitology 1994; 54: 367-73.
21. Poli A, Sozzi S, Guidi G et al. Trattamento della leishmaniosi canina con amminosidina: influenza della terapia sulla risposta anticorpale specifica e sulle concentrazioni delle proteine del siero. Rivista di Zootecnia Veterinaria 1995; 23: 7-12.
22. Denerolle P. Leishmaniose canine: difficultés du diagnostic et du traitement. Pratique Médicale et Chirurgicale de l'Animal de Compagnie 1996; 31: 137-45.
23. Vouldoukis I, Drapier JC, Nuessler K et al. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the 1-arginine nitric oxide pathway. Antimicrobial Agents and Chemotherapy 1996; 40: 253-6.
24. Bourdoiseau G, Bonnefont C, Chabanne L et al. Modifications sanguines (cellulaires et humorales) chez le chien leishmanien. Suivi de chiens infectés traités et non traités. Revue de Médicine Vétérinaire 1997; 148: 219-28.
25. Slappendel RJ, Teske E. The effect of intravenous or subcutaneous administration of meglumine antimoniate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Veterinary Quarterly 1997; 19: 10-13.
26. Poli A, Sozzi S, Guidi G et al. Comparison of aminosidine (paromycin) and sodium stibogluconate for treatment of canine leishmaniasis. Veterinary Parasitology 1997; 71: 263-71.
27. Oliva G, Gradoni L, Cortese L et al. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis. Annals of Tropical Medicine and Parasitology 1998; 92: 165-71.
28. Denerolle P, Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). Journal of Veterinary International Medicine 1999; 13: 413-15.
29. Moritz A, Steuber S, Greiner M. Clinical follow-up after treatment of canine leishmaniasis. Tokai Journal of Experimental Clinical Medicine 1999; 23: 279-83.
30. Riera C, Valladares JE, Gàllego M et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with megumine antimoniate. Veterinary Parasitology 1999; 84: 33-47.
31. Valladares JE, Riera C, Gonzàlez-Ensenyat P et al. Long-term improvement in the treatment of canine leishmaniosis using an antimony liposomial formulation. Veterinary Parsitology 2001; 97: 15-21.
32. Bianciardi P, Fasanella A, Foglia Manzillo V et al. The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis. Parasitology Research 2004; 93: 486-92.
33. Alvar J, Molina R, San Andrés M et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Annals of Tropical Medicine and Parasitology 1994; 88: 371-8.
34. Ferrer L, Aisa MJ, Roura X et al. Serological diagnosis and treatment of canine leishmaniasis. Veterinary Record 1995; 136: 514-16.
35. Ginel PJ, Lucena R, Lòpez R et al. Use of allopurinol for maintenance of remission in dogs with leishmaniasis. Journal of Small Animal Practice 1998; 39: 271-4.
36. Roura X, Sanchez A, Ferrer L. Diagnosis of canine leishmaniasis by a polymerase chair reaction technique. Veterinary Record 1999; 144: 262-4.
37. Pennisi MG, De Majo M, Masucci M et al. Efficacy of metronidazole- spiramycin combined therapy in the treatment of canine leishmaniasis. Veterinary Record 2005; 156: 346-9.
38. Martinez-Subiela S, Bernal LJ, Ceron JJ. Serum concentrations of acute-phase proteins in dogs with leishmaniasis during short-term treatment. American Journal of Veterinary Research 2003; 64: 1021-6.
39. Vercammen F, De Deken R, Kageruka P. First evaluation of the use of allopurinol as a single drug for the treatment of canine leishmaniosis. Vlaams Diergeneeskundig Tijdschrift 1995; 64: 208-14.
40. Gothe R, Nolte I, Kraft W. Leismaniose des Hundes in Deutschland: epidemiologische Fallanalyse und Alternative zur bisherigen kausalen Therapie. Tieraerztliche Praxis 1997; 25: 68-73.
41. Cavaliero T, Arnold P, Mathis A et al. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. Journal of Veterinary International Medicine 1999; 13: 330-4.
42. Slappendel R, Teske E. A review of canine leishmaniasis presenting outside endemic areas. In: Killick-Kendrick R ed. Canine Leishmaniasis: an update. Hoechst Russel Vet 1999: 54-9.
43. Koutinas AF, Saridomichelakis MN, Mylonakis ME et al. A randomized, blinded, placebo controlled clinical trial with allopurinol in canine leishmaniasis. Veterinary Parasitology 2001; 98: 247-61.
44. Persechino A, Oliva G, Ciaramella P et al. Impiego dell'amminosidina nella terapia della leishmaniosi del cane. Nota I. Rivista Di Zootecnia Veterinaria 1994; 22: 116.
45. Persechino A, Oliva G, Ciaramella P et al. Impiego dell'amminosidina nella terapia della leishmaniosi del cane. Nota II. Rivista Di Zootecnia Veterinaria 1995; 23: 3-6.
46. Vexenat JA, Olliaro PL, Fonseca de Castro JA et al. Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromycin). American Journal of Tropical Medicine and Hygiene 1998; 58: 448-53.
47. Oliva G, Gradoni L, Ciaramella P et al. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. Journal of Antimicrobial Chemotherapy 1995; 36: 1013-19.
48. Lamothe J. Essai de traitement de la leishmaniose canine par l'amphotéricine B (39 cas). Pratique Médicale et Chirurgicale de l'Animal de Compagnie 1997; 32: 133-41.
49. Lamothe J. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. Journal of Small Animal Practice 2001; 42: 170-5.
50. Cortadellas O. Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis. Journal of Veterinary International Medicine 2003; 17: 808-12.
51. D'Ambrosio C, Gallo C, Agresti A. Il ketoconazolo nella terapia della leishmaniosi del cane. Atti SISVET 1986; 40: 492-6.
52. Vexenat JA, Croft SL, Furtado Campos JH et al. Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis. Veterinary Parasitology 1998; 77: 71-3.
53. Rhalem A, Sahibi H, Lasri S et al. Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after drug treatment. Veterinary Immunology and Immunopathology 1999; 71: 69-76.
54. Lasri S, Sahibi H, Natami A et al. Western blot analysis of Leishmania infantum antigens using sera from pentamidine-treated dogs. Veterinary Immunology and Immunopathology 2003; 91: 13-8.
55. Maroli M, Mizzoni V, Siragusa C et al. Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin-impregnated dog collars in southern Italy. Medical and Veterinary Entomology 2001; 15: 358-63.
56. Giffoni JH, de Almeida CE, dos Santos SO et al. Evaluation of 65% permethrin spot-on formulation for prevention of canine visceral leishmaniasis: effect on disease prevalence and the vectors (Diptera: Psychodidae) in a hyperendemic area. Veterinary Therapeutics 2002; 3: 485-92.
57. Mazloumi Gavgani AS, Hodjati MH, Mohite H et al. Effect of insecticidal impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched cluster randomized trial. Lancet 2002; 360: 374-9.
58. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. British Medical Journal 2001; 323: 42-6.
59. Valladares JE, Riera C, Alberola J et al. Pharmacokinetics of meglumine antimoniate after administration of multiple doses in dogs experimentally infected with Leishmania infantum. Veterinary Parasitology 1998; 75: 33-40.
60. Ling GV, Ruby AL, Harrold DR et al. Xanthine-containing urinary calculi in dogs given allopurinol. Journal of the American Veterinary Medical Association 1991; 11: 1935-40.